Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells

JAMA Oncol. 2016 Jan;2(1):134-6. doi: 10.1001/jamaoncol.2015.3940.

Authors

Charles L Bennett¹, Stephen Y Lai², Oliver Sartor³, Peter Georgantopoulos¹, William J Hrushesky⁴, Michael Henke⁵, James O Armitage⁶

Affiliations

¹ South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, University of South Carolina, Columbia.
² Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.
³ Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.
⁴ Oncology Analytics Inc, Plantation, Florida.
⁵ Clinic for Radiation Oncology, Universitätsklinikum, Freiburg, Germany.
⁶ Department of Medicine, University of Nebraska Medical Center, Omaha.

PMID: 26606114
DOI: 10.1001/jamaoncol.2015.3940

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Review

MeSH terms

Academies and Institutes
Anemia / blood
Anemia / chemically induced
Anemia / drug therapy*
Antineoplastic Agents / adverse effects
Blotting, Western / standards
Consensus
Consensus Development Conferences, NIH as Topic
Drug Industry
Erythropoietin / adverse effects
Erythropoietin / metabolism
Erythropoietin / therapeutic use*
Hematinics / adverse effects
Hematinics / metabolism
Hematinics / therapeutic use*
Humans
Neoplasms / drug therapy
Neoplasms / genetics
Neoplasms / metabolism*
Neoplasms / pathology
Observer Variation
Predictive Value of Tests
Receptors, Erythropoietin / agonists
Receptors, Erythropoietin / genetics
Receptors, Erythropoietin / metabolism*
Reproducibility of Results
Reverse Transcriptase Polymerase Chain Reaction / standards
Risk Assessment
United States

Substances

Antineoplastic Agents
Hematinics
Receptors, Erythropoietin
Erythropoietin